Royalty Pharma reported cash from operations of $728.46M and free cash flow of $728.46M for the quarter ended Jun 2026, up 100.1% year over year. This cash flow statement covers 29 quarters of results from Jun 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow StatementCash Flow | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||
| Net Income | 221.80M | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | |||||||||
| Asset Writedowns and Impairment | 69.40M | ||||||||||||||||||||||||||||
| Other non-cash items | 6.21M | 6.17M | 20.69M | 6.81M | 5.81M | 5.83M | 16.27M | 2.24M | 0.31M | 13.40M | 13.40M | 3.72M | 21.02M | ||||||||||||||||
| Other Operating ActivitiesOther Operating | |||||||||||||||||||||||||||||
| Cash from Operations | 469.76M | 489.96M | 460.27M | 574.95M | 538.83M | 569.93M | 1,033.84M | 607.82M | 573.52M | 772.63M | 664.64M | 658.21M | 703.61M | 742.53M | 596.08M | 363.98M | 702.62M | 827.15M | 718.23M | 728.46M | |||||||||
| Investing Activities | |||||||||||||||||||||||||||||
| Investment Securities | |||||||||||||||||||||||||||||
| Purchase of AFS Securities | 17.59M | 17.69M | 64.58M | 14.58M | 314.58M | 85.82M | 100.00M | ||||||||||||||||||||||
| Purchase of Investments - Total | 156.13M | 500.25M | 278.98M | 122.09M | 321.43M | 110.82M | 3.58M | 2.99M | 3.98M | 1.99M | 6.97M | 71.98M | 12.50M | 4.43M | 154.00M | 22.50M | 5.00M | ||||||||||||
| Sale of AFS Securities | 15.63M | 15.63M | 15.63M | 15.63M | 15.63M | 495.17M | 1.44M | 1.44M | 2.88M | 2.88M | 12.59M | 12.59M | 2.88M | 2.88M | 2.88M | 4.32M | 4.32M | ||||||||||||
| Sale and Maturity of Investments - Total | 640.07M | 120.34M | 290.23M | 266.92M | 166.42M | 610.81M | 59.16M | 4.46M | 6.10M | 6.41M | 6.82M | 14.37M | 15.83M | 48.85M | 65.87M | 3.79M | 7.87M | 46.63M | -8.89M | ||||||||||
| Purchases of Loans | 1,336.03M | 171.73M | 0.09M | 175.01M | 1,316.31M | 250.24M | 601.71M | 60.45M | 451.13M | 1,002.24M | 86.08M | 728.63M | 1,194.57M | 496.42M | 1.06M | 1.11M | 961.87M | 733.69M | 452.37M | 251.02M | |||||||||
| Acquisitions | 0.23M | ||||||||||||||||||||||||||||
| Other Investing ActivitiesOther Investing | 6.59M | 46.16M | 165.00M | -12.40M | -2.04M | -99.39M | 0.00M | -25.00M | 460.55M | -376.74M | 32.01M | -49.63M | 35.19M | ||||||||||||||||
| Cash from Investing Activities | -845.50M | -551.65M | 11.17M | -30.18M | -1,425.15M | 414.74M | -558.53M | -63.43M | -450.66M | -1,000.17M | -86.65M | -893.18M | -1,192.70M | -505.59M | 503.92M | -311.98M | -958.31M | -847.80M | -477.87M | -229.72M | |||||||||
| Financing Activities | |||||||||||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||||||||
| Long-Term Debt Issuances | 1,272.53M | 350.00M | 3,229.48M | ||||||||||||||||||||||||||
| Long-Term Debt Repayments | |||||||||||||||||||||||||||||
| Net Long-Term Debt Issued (Repaid)Net LT Debt | 1,272.53M | 350.00M | 3,229.48M | ||||||||||||||||||||||||||
| Net Debt Issuances and Repayments | 1,272.53M | 350.00M | 3,229.48M | ||||||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||||||
| Common Stock IssuedStock Issued | |||||||||||||||||||||||||||||
| Shares Repurchased | 140.12M | 30.20M | 80.00M | 97.05M | 52.61M | 708.78M | 291.57M | 146.49M | 80.54M | 50.10M | 44.64M | ||||||||||||||||||
| Net Shares Issued and Repurchased | -140.12M | -30.20M | -80.00M | -97.05M | -52.61M | -708.78M | -291.57M | -146.49M | -80.54M | -50.10M | -44.64M | ||||||||||||||||||
| Net Equity Issued and Repurchased | -140.12M | -30.20M | -80.00M | -97.05M | -52.61M | -708.78M | -291.57M | -146.49M | -80.54M | -50.10M | -44.64M | ||||||||||||||||||
| Dividend Payments | |||||||||||||||||||||||||||||
| Dividends Paid - Common and PreferredDividends Paid | 73.02M | 73.60M | 82.26M | 83.05M | 83.81M | 84.20M | 88.63M | 90.61M | 89.75M | 89.34M | 93.81M | 94.94M | 94.06M | 93.66M | 95.36M | 93.24M | 95.31M | 94.34M | 104.49M | 104.92M | |||||||||
| Other Financing ActivitiesOther Financing | -165.25M | -124.47M | -138.70M | -145.21M | -146.28M | -181.35M | -121.74M | -256.39M | -1,129.62M | -462.36M | -118.19M | 1,331.55M | -134.40M | -111.70M | -137.16M | -123.00M | -2,424.94M | -124.72M | -118.08M | -123.59M | |||||||||
| Cash from Financing Activities | 1,034.27M | -198.07M | -220.97M | -228.25M | -230.09M | -265.55M | -210.37M | -347.00M | -1,359.49M | -231.89M | -212.00M | 1,156.61M | -325.51M | -257.96M | -941.30M | -507.81M | 562.74M | -299.60M | -272.67M | -273.15M | |||||||||
| Misc. | |||||||||||||||||||||||||||||
| Change in Cash | 658.53M | -259.76M | 250.47M | 316.52M | -1,116.41M | 719.12M | 264.94M | 197.39M | -1,236.63M | -459.44M | 365.99M | 921.64M | -814.59M | -21.03M | 158.69M | -455.81M | 307.04M | -320.25M | -32.30M | 225.59M | |||||||||
| Ending Cash Balance | 1,800.81M | 1,541.05M | 1,791.52M | 2,108.04M | 991.63M | 1,710.75M | 1,975.69M | 2,173.08M | 936.45M | 477.01M | 843.00M | 1,764.64M | 950.05M | 929.03M | 1,087.72M | 631.91M | 938.94M | 618.70M | 586.40M | 811.99M | |||||||||
| Net Cash Flow | 658.53M | -259.76M | 250.47M | 316.52M | -1,116.41M | 719.12M | 264.94M | 197.39M | -1,236.63M | -459.44M | 365.99M | 921.64M | -814.59M | -21.03M | 158.69M | -455.81M | 307.04M | -320.25M | -32.30M | 225.59M | |||||||||
| Free Cash Flow | 469.76M | 489.96M | 460.27M | 574.95M | 538.83M | 569.93M | 1,033.84M | 607.82M | 573.52M | 772.63M | 664.64M | 658.21M | 703.61M | 742.53M | 596.08M | 363.98M | 702.62M | 827.15M | 718.23M | 728.46M | |||||||||
| Supplemental | |||||||||||||||||||||||||||||
| Interest Paid | 65.26M | 0.67M | 86.22M | 0.66M | 82.60M | 0.66M | 82.59M | 0.66M | 82.59M | 3.33M | 78.97M | 0.80M | 79.00M | 0.81M | 138.82M | 0.80M | 129.99M | 6.68M | 173.53M | 5.35M |
Pull Royalty Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=RPRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "RPRX", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=RPRX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();